Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2013
At a glance
- Drugs Imatinib (Primary) ; Sorafenib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 29 Sep 2009 Planned end date changed from Jan 2011 to Jan 2013 as reported by ClinicalTrials.gov.
- 13 Feb 2007 New trial record.